Non Small Cell Lung Cancer Clinical Trial
Official title:
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively and Prospectively as First Line Treatment for Patients With Advanced or Metastatic Non Small Cell Lung Cancer. Assessment of Toxicity, Compliance and Survival of Patients.
Investigators propose to assess, retrospectively and prospectively the safety and
tolerability profile (number of participants with adverse events) of standard chemotherapy
and anti-angiogenic agent bevacizumab (Avastin) as first line treatment of patients with
advanced or metastatic Non Small Cell Lung Cancer.
All treatment schedules that are going to be assessed are considered by the international
guidelines as standard therapy for patients with advanced or metastatic Non Small Cell Lung
Cancer.
Status | Completed |
Enrollment | 300 |
Est. completion date | December 2013 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed informed consent prior to initiation of any trial-specific procedure or treatment - Ability to comply with the protocol - Histologically or cytologically (sample to be obtained by biopsy or bronchoscopy) confirmed non-squamous NSCLC (locally recurrent or metastatic) per investigator assessment - At least 1 unidimensionally measurable lesion meeting RECIST criteria - No prior first line treatment for metastatic colorectal cancer - Age =18 years - ECOG performance status =2 - Adequate haematological, renal and hepatic function - Urine protein <2+ (dipstick) - International normalized ratio (INR) = 1.5 and activated partial thromboplastin time (aPTT) = 1.5 x ULN within 7 days prior to randomization, unless there is prophylactic use of anti-coagulation - Patients with asymptomatic treated brain metastases are eligible for trial participation. Patients must complete treatment for brain metastases (radiotherapy with or without surgery, or stereotactic radiosurgery), including steroids, at least 28 days prior to randomization. Treatment with anticonvulsants at the time of randomization (i.e. = 28 days) is allowed as long as the anti-convulsant is at a stable dose) - Female patients must not be pregnant or breast-feeding. Female patients of childbearing potential (defined as >2 years after last menstruation or surgically sterile) must use a highly effective contraceptive method (allowed methods of birth control, i.e. with a failure rate of less than 1% per year, are implants, injectables, combined oral contraceptives, intra-uterine device [IUD; only hormonspirals], sexual abstinence or vasectomized partner) during the trial and for a period of at least 6 months following the last administration of trial drug(s).Female patients with an intact uterus (unless amenorrhoeic for the last 24 months) must have a negative serum pregnancy test within 7 days prior to randomization into the trial - Fertile male patients must agree to use a highly effective contraceptive method (allowed methods of birth control, i.e. with a failure rate of less than 1% per year, include a female partner using implants, injectables, combined oral contraceptives, IUDs [only hormonspirals], sexual abstinence or prior vasectomy) during the trial and for a period of at least 6 months following the last administration of trial drug(s) Exclusion Criteria: - Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component - History of hemoptysis = grade 2 (defined as bright red blood of at least 2.5 mL) within 3 months prior to randomization - Surgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during trial treatment - Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion - Evidence of tumor invading or abutting a major blood vessel (e.g., pulmonary artery or superior vena cava) on imaging - Radiotherapy to any site for any reason within 28 days prior to randomization. Palliative radiotherapy to bone lesions within 14 days prior to randomization is allowed - Current or recent (within 10 days prior to first dose of bevacizumab) use of aspirin (> 325 mg/day), clopidogrel (> 75 mg/day), or current or recent (within 10 days prior to first dose of bevacizumab) use of full-dose (i.e. therapeutic dose) oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed. - History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding - Active gastrointestinal bleeding - Inadequately controlled hypertension (blood pressure: systolic > 150 mmHg and/or diastolic > 100 mmHg) within 28 days prior to randomization or history of hypertensive crisis or hypertensive encephalopathy - Clinically significant (i.e. active) cardiovascular disease (e.g. cerebrovascular accident [CVA] or myocardial infarction within 6 months prior to randomization, unstable angina, congestive heart failure [CHF] New York Heart Association [NYHA] Class = II, or serious cardiac arrhythmia), that is uncontrolled by medication or may interfere with administration of trial treatment - Non-healing wound, active peptic ulcer or untreated bone fracture - History of abdominal fistula, gastrointestinal perforation or intra abdominal abscess within 6 months prior to randomization. - Treatment with any other investigational agent within 28 days prior to randomization. Patients in the follow-up phase of 1st-line trials who fulfill all eligibility criteria may be enrolled in this trial if the 1st-line protocol allows bevacizumab-based treatment in the follow-up phase - Known hypersensitivity to bevacizumab or any of its excipients, or any of the SOC agents foreseen - Malignancy other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent, and ductal carcinoma in situ (DCIS) treated surgically with curative intent - Evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational or SOC drug used in this study or puts the patient at higher risk for treatment-related complications |
Observational Model: Cohort
Country | Name | City | State |
---|---|---|---|
Greece | University General Hospital of Alexandroupolis, Dept. of Medical Oncology | Alexandroupolis | |
Greece | "IASO" General Hospital of Athens | Athens | |
Greece | 401 Military Hospital of Athens | Athens | |
Greece | Air Forces Military Hospital of Athens | Athens | |
Greece | University Hospital of Crete, Dep of Medical Oncology | Heraklion | Crete |
Greece | State General Hospital of Larissa, Dep of Medical Oncology | Larissa | |
Greece | "Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology | Piraeus | |
Greece | "Theagenion" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology | Thessaloniki |
Lead Sponsor | Collaborator |
---|---|
Hellenic Oncology Research Group |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with AE | In this observational study investigators are going to assess standard schedules in which administrations were every 3 weeks. | Every 3 weeks up to 18 weeks | Yes |
Secondary | Number of Participants with Response Rate | In this observational study investigators are going to assess standard schedules in which the disease evaluation was performed every 6 weeks | Disease evaluation at Week 6 | No |
Secondary | Percentage of Patients with Progression Free Survival | 1 year | No | |
Secondary | Patients Overall Survival | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |